In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Stephen M. McLean net worth and biography

Stephen McLean Biography and Net Worth

Director of Certara

Mr. McLean is the Senior Partner, Healthcare Group at Arsenal Capital Partners, a New York City-based private equity firm. Previously, Mr. McLean was a founding Partner of Merrill Lynch Capital Partners, Inc. McLean serves on a number of corporate boards including WCG Clinical, CellCarta, BioIVT and Value Demonstration. He is the Chairman and a founder of the International Biomedical Research Alliance. McLean holds a BS in Economics, summa cum laude and an MBA with Distinction, both earned from the Wharton School of the University of Pennsylvania.

What is Stephen M. McLean's net worth?: The estimated net worth of Stephen M. McLean is at least $401,100.00 as of August 19th, 2022. Mr. McLean owns 42,000 shares of Certara stock worth more than $401,100 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. McLean may own. Learn More about Stephen M. McLean's net worth.
How do I contact Stephen M. McLean?: The corporate mailing address for Mr. McLean and other Certara executives is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. Certara can also be reached via phone at 609-716-7900 and via email at [email protected]. Learn More on Stephen M. McLean's contact information.
Has Stephen M. McLean been buying or selling shares of Certara?: Stephen M. McLean has not been actively trading shares of Certara within the last three months. Most recently, on Friday, August 19th, Stephen M. Mclean bought 20,000 shares of Certara stock. The stock was acquired at an average cost of $16.32 per share, with a total value of $326,400.00. Following the completion of the transaction, the director now directly owns 42,000 shares of the company's stock, valued at $685,440. Learn More on Stephen M. McLean's trading history.
Who are Certara's active insiders?: Certara's insider roster includes Robert Aspbury (Insider), Eran Broshy (Director), James Cashman, III (Director), Jieun Choe (Insider), Justin Edge (Insider), William Feehery (CEO), Stephen McLean (Director), Leif Pedersen (Insider), Craig Rayner (Insider), Michael Schemick (CFO), Mason Slaine (Director), Patrick Smith (Insider), Richard Traynor (SVP), and Matthew Walsh (Director). Learn More on Certara's active insiders.
Are insiders buying or selling shares of Certara?: During the last year, insiders at the sold shares 6 times. They sold a total of 86,060 shares worth more than $1,151,075.18. The most recent insider tranaction occured on October, 7th when insider Patrick F Smith sold 5,409 shares worth more than $59,661.27. Insiders at Certara own 2.4% of the company. Learn More about insider trades at Certara.
Information on this page was last updated on 10/7/2024.

Stephen M. McLean Insider Trading History at Certara

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/19/2022	Buy	20,000	$16.32	$326,400.00	42,000

Stephen M. McLean Buying and Selling Activity at Certara

Certara Company Overview

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $9.51

$9.45

$9.60

50 Day Range

MA: $10.82

$9.55

$11.75

2 Week Range

Now: $9.51

$9.45

$19.87

Volume

85,604 shs

Average Volume

789,852 shs

Market Capitalization

$1.53 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad